REPLIGEN CORPRGENEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12.70% | 7.1M | flat | 2024-11-12 |
| T. ROWE PRICE ASSOCIATES, INC. | 11.40% | 6.4M | ▲ +0.50pp | 2024-11-14 |
| The Vanguard Group | 9.10% | 5.1M | — | 2024-02-13 |
| Roy T. Eddleman Living Trust | 4.85% | 2.7M | — | 2024-02-06 |
Insider Transactions
Net 90d: −$536.5K · buys $0 / sells $536.5KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-21 | Olivier Loeillot | Chief Executive Officer | Sell (open market) | 3.8K | $140.00 | $536.5K |
| 2026-03-05 | KURIYEL RALF | Senior VP, R&D | Grant | 5.3K | $0.00 | $0 |
| 2026-03-05 | Olivier Loeillot | Chief Executive Officer | Grant | 24.1K | $0.00 | $0 |
| 2026-03-05 | Garland Jason K | CFO | Grant | 7.8K | $0.00 | $0 |
| 2026-03-05 | James Bylund | Chief Operating Officer | Grant | 7.8K | $0.00 | $0 |
| 2026-03-04 | James Bylund | Chief Operating Officer | Grant | 125 | $0.00 | $0 |
| 2026-03-04 | KURIYEL RALF | Senior VP, R&D | Grant | 125 | $0.00 | $0 |
1–7 of 7